New approaches in the prevention and treatment of pancreatic cancer in subjects with metabolic disorders

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023001%3A_____%2F25%3A00086092" target="_blank" >RIV/00023001:_____/25:00086092 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

New approaches in the prevention and treatment of pancreatic cancer in subjects with metabolic disorders

Popis výsledku v původním jazyce

Pancreatic ductal adenocarcinoma (PDAC) demonstrates increased aggressivenessand reduced overall survival especially in patients with obesity and diabetes, likely due tometabolic dysregulation, chronic inflammation, and insulin resistance contributing to tumorprogression. Despite extensive research, limited efficacy of current therapies have prompted asearch for novel therapeutic options. An example is the therapeutic influence of cellularsenescence, which plays a critical role in the development and progression of PDAC in patientswith metabolic diseases. Our goal was therefore to test the novel mitochondria-targeted senolyticcompound (Compound X), developed in our laboratory, on prevention and treatment of PDAC.

Název v anglickém jazyce

New approaches in the prevention and treatment of pancreatic cancer in subjects with metabolic disorders

Popis výsledku anglicky

Pancreatic ductal adenocarcinoma (PDAC) demonstrates increased aggressivenessand reduced overall survival especially in patients with obesity and diabetes, likely due tometabolic dysregulation, chronic inflammation, and insulin resistance contributing to tumorprogression. Despite extensive research, limited efficacy of current therapies have prompted asearch for novel therapeutic options. An example is the therapeutic influence of cellularsenescence, which plays a critical role in the development and progression of PDAC in patientswith metabolic diseases. Our goal was therefore to test the novel mitochondria-targeted senolyticcompound (Compound X), developed in our laboratory, on prevention and treatment of PDAC.

Druh

O - Ostatní výsledky

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

<a href="/cs/project/LX22NPO5104" target="_blank" >LX22NPO5104: Národní institut pro výzkum metabolických a kardiovaskulárních onemocnění</a><br>

Návaznosti

P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Rok uplatnění

2025

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů